Jubilant LifeScience has informed that material wholly-owned subsidiary, Jubilant Pharma (JPL) has given notice to the holders of its $300,000,000 4.875% Senior Notes due 2021 (the Notes) that it has elected to exercise its option to redeem $100,000,000 in aggregate principal amount of the Notes on November 20, 2019 (the Redemption Date) pursuant to the terms of the indenture dated as of October 6, 2016 (the Indenture) between JPL and The Bank of New York Mellon, London Branch as trustee, governing the Notes. Pursuant to the terms of the Indenture, the redemption price for the Notes will be equal to 102.43750% of the principal amount of such Notes, plus accrued and unpaid interest thereon, to (but not including) the Redemption Date (the Redemption Price). The Notes will be redeemed on a pro rata basis. The above information is a part of company’s filings submitted to BSE.
